Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 11,500.00
Ask: 12,270.00
Change: 0.00 (0.00%)
Spread: 770.00 (6.696%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Dec 2021 15:00

RNS Number : 7755V
AstraZeneca PLC
15 December 2021
 

15 December 2021 15:00 GMT

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announces that Tony Mok, a Non-Executive Director of the Company, purchased 2,000 of the Company's American Depositary Shares (ADSs) on 13 December 2021. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.

 

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Tony Mok

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

AstraZeneca PLC American Depositary Shares

 

 

CUSIP: 046353108

b)

 

Nature of the transaction

 

 

Purchase of AstraZeneca PLC American Depositary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$54.29

2,000

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

13 December 2021

f)

 

Place of the transaction

 

XNAS

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUVOORAOUUAAA
Date   Source Headline
2nd Oct 20233:00 pmRNSTotal Voting Rights
22nd Sep 20237:00 amRNSDato-DXd improved PFS in breast cancer
20th Sep 20237:00 amRNSAlexion completes Pfizer gene therapy agreement
15th Sep 20233:00 pmRNSEnhertu recommended in EU for HER2-mutant NSCLC
11th Sep 20234:00 pmRNSFasenra Phase III EGPA trial met primary endpoint
6th Sep 20237:00 amRNSUpdate on US review of Ultomiris for NMOSD
1st Sep 20233:00 pmRNSTotal Voting Rights
1st Aug 20233:00 pmRNSTotal Voting Rights
28th Jul 20237:05 amRNSAlexion enters gene therapy agreement with Pfizer
28th Jul 20237:00 amRNSHalf-year Report
17th Jul 20236:10 pmRNSBeyfortus approved in US for infant RSV prevention
3rd Jul 20233:00 pmRNSTotal Voting Rights
3rd Jul 20237:00 amRNSDato-DXd significantly improved PFS in lung cancer
9th Jun 20237:05 amRNSnirsevimab recommended for infant RSV protection
9th Jun 20237:00 amRNSAstraZeneca agreement with Quell Therapeutics
2nd Jun 20235:00 pmRNSImfinzi improved pCR in gastric and GEJ cancers
1st Jun 20233:05 pmRNSBlock listing Interim Review
1st Jun 20233:00 pmRNSTotal Voting Rights
1st Jun 20237:00 amRNSLynparza approved in US for BRCAm prostate cancer
26th May 20237:00 amRNSImfinzi + Lynparza prolonged PFS in endometrial ca
22nd May 20237:05 amRNSDirectorate Change
17th May 20237:00 amRNSTagrisso plus chemo improved PFS in lung cancer
9th May 202311:00 amRNSDirector/PDMR Shareholding
9th May 20237:00 amRNSFarxiga extended in the US for heart failure
2nd May 20233:00 pmRNSTotal Voting Rights
2nd May 202310:00 amRNSDirector/PDMR Shareholding
2nd May 20237:00 amRNSODAC vote on Lynparza combo in prostate cancer
27th Apr 20235:30 pmRNSResult of AGM
27th Apr 20237:05 amRNSBoard Committee Changes
27th Apr 20237:00 amRNS1st Quarter Results
26th Apr 20234:45 pmRNSDirector Declaration
11th Apr 20237:00 amRNSUpdate to arrangements with Sobi and Sanofi
5th Apr 20237:00 amRNSLynparza + Imfinzi met endpoint in ovarian cancer
3rd Apr 20233:00 pmRNSTotal Voting Rights
3rd Apr 20237:00 amRNSUltomiris recommended for NMOSD EU approval
30th Mar 20237:00 amRNSAstraZeneca completes KYM agreement for CMG901
27th Mar 202311:00 amRNSDirector/PDMR Shareholding
22nd Mar 202311:00 amRNSNotice of AGM
9th Mar 20237:00 amRNSImfinzi improved EFS in resectable lung cancer
8th Mar 202311:01 amRNSDirector/PDMR Shareholding
8th Mar 202311:00 amRNSDirector/PDMR Shareholding
6th Mar 20237:00 amRNSEnhertu DESTINY-PanTumor02 shows positive results
1st Mar 20233:00 pmRNSTotal Voting Rights
1st Mar 20237:00 amRNSAstraZeneca prices a $2.25bn bond offering
24th Feb 20236:15 pmRNSAstraZeneca prices a EUR1.5bn bond offering
24th Feb 20232:05 pmRNSAstraZeneca acquires CinCor for cardiorenal asset
24th Feb 202311:00 amRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSAstraZeneca enters agreement with KYM for CMG901
22nd Feb 20237:10 amRNSFiling of Form 20-F with SEC
21st Feb 202311:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.